Immunotherapy and urothelial carcinoma: An overview and future prospectives

Francesco Pierantoni, Marco Maruzzo, Mario Gardi, Elisabetta Bezzon, Marina Paola Gardiman, Angelo Porreca, Umberto Basso, Vittorina Zagonel

Research output: Contribution to journalReview article

Abstract

BACKGROUND: Urothelial carcinoma (UC) is a common malignancy with a high mortality rate when metastatic. Traditionally, systemic therapy consisted in platinum-based regimens as first-line, with Taxanes or Vinflunine as further lines. Recently, checkpoint inhibitors (CPIs) immunotherapy has emerged as a new therapeutic option.

METHODS: We searched in Medline, Pubmed and ClinicalTrial.gov databases for the relevant literature, reviewing the results of published trials and the design of ongoing studies involving CPIs in UC.

RESULT: Strong evidence supports the use of CPIs after failure of Cisplatin-based chemotherapy, although no predictive parameter is available so far. Expression of Programmed-Death-1-Ligand has given conflicting results, and is currently indicated only for the selection of Cisplatin-ineligible patients who should receive CPIs.

CONCLUSION: The therapeutic landscape of UC is rapidly changing due to the availability of CPIs. Neoadjuvant trials with CPIs and trials combining two CPIs are promising and will further expand the use of immunotherapy.

Original languageEnglish
Pages (from-to)46-55
Number of pages10
JournalCritical Reviews in Oncology/Hematology
Volume143
DOIs
Publication statusPublished - Nov 2019

Keywords

  • Antibodies, Monoclonal/therapeutic use
  • Antineoplastic Agents, Immunological/therapeutic use
  • B7-H1 Antigen/antagonists & inhibitors
  • Humans
  • Immunotherapy/methods
  • Neoadjuvant Therapy
  • Randomized Controlled Trials as Topic
  • Urinary Bladder Neoplasms/drug therapy
  • Urologic Neoplasms/drug therapy

Fingerprint Dive into the research topics of 'Immunotherapy and urothelial carcinoma: An overview and future prospectives'. Together they form a unique fingerprint.

  • Cite this